The favourable reimbursement scenario for dialysis treatment is a key factor driving the growth of the market. Government programs such as Medicare provide extensive coverage for dialysis treatment, making it more accessible to patients with ESRD.
In the U.S., Medicare automatically covers individuals diagnosed with ESRD, regardless of age, ensuring that a large portion of the costs associated with dialysis, including both in-center and home dialysis, are covered. This comprehensive coverage significantly reduces the financial burden on patients, encouraging more individuals to seek and continue necessary treatment, thereby boosting the overall demand for dialysis services and equipment.
The broad and reliable coverage provided by Medicare significantly reduces the out-of-pocket expenses for patients, making dialysis treatment more financially accessible and ensuring continuous care for those in need. This ease of access encourages more patients to opt for regular dialysis, thereby driving up the demand for dialysis services and related products.
Additionally, the reimbursement rates set by Medicare often influence private insurance companies, leading them to offer similar coverage, further expanding access to dialysis treatment across the population. This comprehensive reimbursement framework is instrumental in fostering growth within the market, as it lowers financial barriers for patients and ensures a steady flow of revenue for dialysis providers.
Authors:
Mariam Faizullabhoy , Gauri Wani
Frequently Asked Questions (FAQ) :
U.S. dialysis industry was valued at USD 28.8 billion in 2023 and is expected to exhibit 5.5% CAGR from 2024 to 2032 attributed to the rising number of end-stage renal diseases (ESRD) patients and increasing incidence of diabetes
The hemodialysis type segment in the market recorded USD 25.4 billion in 2023 as it is the standard treatment for the majority of patients with ESRD, particularly those who may not be candidates for home-based therapies.
South Atlantic U.S. dialysis industry size is anticipated to grow at 5.1% CAGR between 2024 and 2032 led by rapidly aging population in Florida, Georgia, and North and South Carolina
Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, DaVita Inc., Fresenius Medical Care AG & Co., Innovative Renal Care., Medtronic plc, Nikkiso Co., Ltd., Nipro Corporation, Toray Industries Inc., and U.S. Renal Care, Inc.